Clinical Cancer Research Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hedley, D.
Right arrow Articles by Hill, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hedley, D.
Right arrow Articles by Hill, R.
Clinical Cancer Research Vol. 9, 5666-5674, November 15, 2003
© 2003 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Carbonic Anhydrase IX Expression, Hypoxia, and Prognosis in Patients with Uterine Cervical Carcinomas

David Hedley145, Melania Pintilie3, Jennifer Woo1, Andrew Morrison1, Diana Birle15, Anthony Fyles2, Michael Milosevic2 and Richard Hill15

1 Division of Experimental Therapeutics and Departments of
2 Radiation Oncology,
3 Biostatistics, and
4 Medical Oncology and Hematology, Ontario Cancer Institute/Princess Margaret Hospital, Toronto, Ontario, and
5 Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada

Purpose: Hypoxia is associated with adverse outcome for a number of solid tumors, including cervical carcinomas. Direct pO2 measurement requires specialized equipment and expertise that is not generally available. Immunohistochemical measurement of intrinsic tissue markers of hypoxia is an alternative approach. Recent studies suggest that carbonic anhydrase IX (CA IX), which is regulated via hypoxia-inducible factor 1, is a useful intrinsic marker of tumor hypoxia.

Experimental Design: Biopsies were obtained from 110 patients with locally advanced cervical carcinoma treated with radiotherapy or chemoradiotherapy. Tissue sections were labeled using an immunofluorescence technique and CA IX expression in the viable tumor area measured using a semiautomated fluorescence image analysis technique. Results were compared with direct pO2 values obtained using an Eppendorf probe and to patient outcome. Intratumoral heterogeneity of CA IX expression was examined in a subgroup of patient who underwent multiple biopsies.

Results: The median percentage of tumor area staining for CA IX was 3.56 (range, 0.01–58.85). CA IX staining did not correlate with the Eppendorf pO2 measurements. Whereas the latter values were predictive of patient outcome, the CA IX levels were not. Measurement of CA IX in multiple biopsies indicated that intratumoral heterogeneity accounted for 41% of the total variance in the data set.

Conclusions: In contrast to some recent studies, we did not find significant associations between CA IX expression and tumor pO2 levels or patient outcome in locally advanced carcinomas of the cervix. Probable explanations relate to the problems of sampling error using single biopsies and the existence of biological factors other than hypoxia that influence CA IX levels.




This article has been cited by other articles:


Home page
Jpn J Clin OncolHome page
S. J. Kim, H. J. Shin, K.-Y. Jung, S.-K. Baek, B. K. Shin, J. Choi, B. S. Kim, S. W. Shin, Y. H. Kim, J. S. Kim, et al.
Prognostic Value of Carbonic Anhydrase IX and Ki-67 Expression in Squamous Cell Carcinoma of the Tongue
Jpn. J. Clin. Oncol., November 1, 2007; 37(11): 812 - 819.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Nakamura, T. Kuwai, Y. Kitadai, T. Sasaki, D. Fan, K. R. Coombes, S.-J. Kim, and I. J. Fidler
Zonal Heterogeneity for Gene Expression in Human Pancreatic Carcinoma
Cancer Res., August 15, 2007; 67(16): 7597 - 7604.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. Bachtiary, P. C. Boutros, M. Pintilie, W. Shi, C. Bastianutto, J.-H. Li, J. Schwock, W. Zhang, L. Z. Penn, I. Jurisica, et al.
Gene Expression Profiling in Cervical Cancer: An Exploration of Intratumor Heterogeneity.
Clin. Cancer Res., October 1, 2006; 12(19): 5632 - 5640.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Mayer, M. Hockel, and P. Vaupel
Carbonic Anhydrase IX Expression and Tumor Oxygenation Status Do Not Correlate at the Microregional Level in Locally Advanced Cancers of the Uterine Cervix
Clin. Cancer Res., October 15, 2005; 11(20): 7220 - 7225.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Mackay, D. Hedley, P. Major, C. Townsley, M. Mackenzie, M. Vincent, P. Degendorfer, M.-S. Tsao, T. Nicklee, D. Birle, et al.
A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer
Clin. Cancer Res., August 1, 2005; 11(15): 5526 - 5533.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Mayer, M. Hockel, A. Wree, and P. Vaupel
Microregional Expression of Glucose Transporter-1 and Oxygenation Status: Lack of Correlation in Locally Advanced Cervical Cancers
Clin. Cancer Res., April 1, 2005; 11(7): 2768 - 2773.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
I. J. Hoogsteen, H. A.M. Marres, K. I.E.M. Wijffels, P. F.J.W. Rijken, J. P.W. Peters, F. J.A. van den Hoogen, E. Oosterwijk, A. J. van der Kogel, and J. H.A.M. Kaanders
Colocalization of Carbonic Anhydrase 9 Expression and Cell Proliferation in Human Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., January 1, 2005; 11(1): 97 - 106.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. J. Kim, Z. N. Rabbani, R. T. Vollmer, E.-G. Schreiber, E. Oosterwijk, M. W. Dewhirst, Z. Vujaskovic, and M. J. Kelley
Carbonic Anhydrase IX in Early-Stage Non-Small Cell Lung Cancer
Clin. Cancer Res., December 1, 2004; 10(23): 7925 - 7933.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Maseide, R. A. Kandel, R. S. Bell, C. N. Catton, B. O'Sullivan, J. S. Wunder, M. Pintilie, D. Hedley, and R. P. Hill
Carbonic Anhydrase IX as a Marker for Poor Prognosis in Soft Tissue Sarcoma
Clin. Cancer Res., July 1, 2004; 10(13): 4464 - 4471.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
D. Hedley, M. Pintilie, J. Woo, T. Nicklee, A. Morrison, D. Birle, A. Fyles, M. Milosevic, and R. Hill
Up-Regulation of the Redox Mediators Thioredoxin and Apurinic/Apyrimidinic Excision (APE)/Ref-1 in Hypoxic Microregions of Invasive Cervical Carcinomas, Mapped Using Multispectral, Wide-Field Fluorescence Image Analysis
Am. J. Pathol., February 1, 2004; 164(2): 557 - 565.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2003 by the American Association for Cancer Research.